These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1848 related articles for article (PubMed ID: 12819933)

  • 1. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
    Workman P
    Cancer Detect Prev; 2002; 26(6):405-10. PubMed ID: 12507224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics.
    Workman P
    Cold Spring Harb Symp Quant Biol; 2005; 70():499-515. PubMed ID: 16869789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
    Porter JR; Fritz CC; Depew KM
    Curr Opin Chem Biol; 2010 Jun; 14(3):412-20. PubMed ID: 20409745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.
    Huth JR; Park C; Petros AM; Kunzer AR; Wendt MD; Wang X; Lynch CL; Mack JC; Swift KM; Judge RA; Chen J; Richardson PL; Jin S; Tahir SK; Matayoshi ED; Dorwin SA; Ladror US; Severin JM; Walter KA; Bartley DM; Fesik SW; Elmore SW; Hajduk PJ
    Chem Biol Drug Des; 2007 Jul; 70(1):1-12. PubMed ID: 17630989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to molecular cancer therapeutics.
    Collins I; Workman P
    Nat Chem Biol; 2006 Dec; 2(12):689-700. PubMed ID: 17108987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of molecular cancer therapeutics.
    van Montfort RL; Workman P
    Trends Biotechnol; 2009 May; 27(5):315-28. PubMed ID: 19339067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemogenomics approaches to novel target discovery.
    Gaither LA
    Expert Rev Proteomics; 2007 Jun; 4(3):411-9. PubMed ID: 17552925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
    Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
    J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
    Workman P
    Cancer Lett; 2004 Apr; 206(2):149-57. PubMed ID: 15013520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
    Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
    Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock".
    Sharma SV; Settleman J
    Biochem Pharmacol; 2010 Sep; 80(5):666-73. PubMed ID: 20211150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 93.